Takara

Takara Bio

For over 50 years, Takara Bio has been committed to helping scientists break new ground with our innovative technologies. Our extensive portfolio of reagents, instruments, and services support advancements in the life sciences, including frontline diagnostics and clinical applications.We are a part of Takara Bio Inc., a world leader in biotechnology research and development based out of Shiga, Japan. Our GMP manufacturing site in West Japan—the first of its kind—enables seamless and sterile handling of viruses, cells, and proteins. Our headquarters in San Jose, CA houses our R&D, marketing, legal, finance, operations, and administrative teams, while our main shipping and warehousing functions are fulfilled at our Madison, WI location. In addition, we have GMP stem cell facilities in Göteborg, Sweden, and the Takara Bio Europe headquarters in France which serves parts of Europe, the Middle East, and Africa.

Content by Takara Bio

 3D illustration of two immune cells interacting with a cancer cell, surrounded by other cells in a red biological environment.
A 3D structure of a double-helix is shown in light purple with numbers representing data on either side against a darker purple background with the shadow of a double-helix.
A 3D-rendered digital illustration of irregularly shaped cells with glowing red nuclei surrounded by a translucent membrane against a black background.
| 5 min read
Multiple viruses in green with protein spikes protruding from the round viral body structure against a light green background
An illustration of cells floating in a blue background
| 3 min read
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Image Alt Text	A laboratorian wearing blue gloves places a PCR sample into a real-time PCR thermocycler, the model shown is blue and white with a large digital screen.
From primer design to sample preparation, explore comprehensive strategies to optimize PCR throughput and reproducibility.
Tackling mycoplasma contamination in biotherapeutic production
DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.
Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue